Literature DB >> 10873836

Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates.

L S Hervio1, G S Coombs, R C Bergstrom, K Trivedi, D R Corey, E L Madison.   

Abstract

BACKGROUND: Understanding the networks of selective proteolysis that regulate complex biological systems requires an appreciation of the molecular mechanisms used to maintain substrate specificity. Human plasmin, a serine protease that promotes the dissolution of blood clots and is essential in maintaining normal hemostasis, is usually described as having broad substrate specificity. Recent evidence that plasmin also plays a key role in a variety of other important biological and pathological processes, however, has suggested that this description might need to be re-evaluated.
RESULTS: We used substrate phage display to elucidate optimal subsite occupancy for substrates of plasmin. We identified a peptide substrate that is cleaved 710,000-fold more efficiently by plasmin than a peptide containing the activation sequence of plasminogen. Plasmin achieves this unexpected, large differential activity even though both target sequences possess an arginine residue in the P1 position. We also demonstrate that proteolysis by plasmin can be targeted to an engineered protein substrate and that introduction of substrate sequences identified by phage display into plasminogen increases plasmin-mediated cleavage of the mutant 2000-fold.
CONCLUSIONS: The specificity of plasmin is more tightly controlled than previously recognized; interactions with substrates at all subsites between S4 and S2' contribute to catalysis. Furthermore, in contrast to most enzymes that exhibit positive selectivity for substrate, the evolution of substrate specificity by plasmin has apparently been dominated by a strong negative selection against development of autoactivation activity. This 'negative selectivity' avoids short-circuiting regulation of the fibrinolytic system and other important biological processes, and might be an important general mechanism for controlling protease cascades.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873836     DOI: 10.1016/s1074-5521(00)00125-3

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  15 in total

1.  Modification of the hemagglutinin cleavage site allows indirect activation of avian influenza virus H9N2 by bacterial staphylokinase.

Authors:  Longping V Tse; Gary R Whittaker
Journal:  Virology       Date:  2015-04-01       Impact factor: 3.616

2.  Engineering fibrin-binding TGF-β1 for sustained signaling and contractile function of MSC based vascular constructs.

Authors:  Mao-Shih Liang; Stelios T Andreadis
Journal:  Biomaterials       Date:  2011-08-23       Impact factor: 12.479

3.  Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.

Authors:  Madhu S Bajaj; Godwin I Ogueli; Yogesh Kumar; Kanagasabai Vadivel; Gregory Lawson; Sreejesh Shanker; Amy E Schmidt; S Paul Bajaj
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

4.  Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus.

Authors:  Xiangjie Sun; Longping V Tse; A Damon Ferguson; Gary R Whittaker
Journal:  J Virol       Date:  2010-06-16       Impact factor: 5.103

5.  A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.

Authors:  W P Sheffield; L J Eltringham-Smith; S Gataiance; V Bhakta
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

6.  Plasmin-mediated activation of pandemic H1N1 influenza virus hemagglutinin is independent of the viral neuraminidase.

Authors:  Longping V Tse; Valerie C Marcano; Weishan Huang; Misty S Pocwierz; Gary R Whittaker
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

7.  Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics.

Authors:  Daniel K Afosah; Rami A Al-Horani; Nehru Viji Sankaranarayanan; Umesh R Desai
Journal:  J Med Chem       Date:  2017-01-05       Impact factor: 7.446

Review 8.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

9.  Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels.

Authors:  Runzhen Zhao; Gibran Ali; Hong-Guang Nie; Yongchang Chang; Deepa Bhattarai; Xuefeng Su; Xiaoli Zhao; Michael A Matthay; Hong-Long Ji
Journal:  Br J Pharmacol       Date:  2020-05-11       Impact factor: 9.473

10.  The role of SERPIN citrullination in thrombosis.

Authors:  Ronak Tilvawala; Venkatesh V Nemmara; Archie C Reyes; Nicoletta Sorvillo; Ari J Salinger; Deya Cherpokova; Saeko Fukui; Sarah Gutch; Denisa Wagner; Paul R Thompson
Journal:  Cell Chem Biol       Date:  2021-08-04       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.